FDA: Increased HBV reactivation risk with ofatumumab or rituximab (Q43837340)
Jump to navigation
Jump to search
scientific article published in October 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | FDA: Increased HBV reactivation risk with ofatumumab or rituximab |
scientific article published in October 2013 |
Statements
1 reference
FDA: Increased HBV reactivation risk with ofatumumab or rituximab (English)
1 reference
Mike Mitka
1 reference
1 October 2013
1 reference
1 reference
310
1 reference
16
1 reference
1664
1 reference
Identifiers
1 reference
1 reference